Tardive Dyskinesias

Hyperkinetic Movement Disorders: Differential Diagnosis and Treatment

Volumn , Issue , 2012, Pages 331-352

  Revuelta, Gonzalo J ^a   Cloud, Leslie ^a   Aia, Pratibha G ^a   Factor, Stewart A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti psychotics; Chorea; Dopamine blockers; Drug induced; Dyskinesia; Dystonia; Iatrogenic; Metoclopramide; Neuroleptic; Tardive

Indexed keywords

EID: 84886000640     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444346183.ch21     Document Type: Chapter

References (224)

1. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs. Am J Psychiat 1980; 137(10):1163-72.
2. Jeste DV, Lacro JP, Palmer B, et al. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiat 1999; 5(2):309-11.
3. Delay J, Deniker P. Trente-huit cas de psychoses traites par la cure prolongee et continue de 4568 R. Ann Med Psychol 1952; 110:364.
4. Schonecker M. [Paroxysmal dyskinesia as the effect of megaphen.]. Nervenarzt 1957; 5(12):550-3.
5. Kruse W. Persistent muscular restlessness after phenothiazine treatment: report of 3 cases. Am J Psychiat 1960; 5:152-3.
6. Hunter R, Earl CJ, Thronicroft S. An Apparently Irreversible Syndrome of Abnormal Movements Following Phenothiazine Medication. Proc R Soc Med 1964; 5:758-62.
7. Faurbye A, Rasch PJ, Petersen PB, et al. Neurological Symptoms in Pharmacotherapy of Psychoses. Acta Psychiatr Scand 1964; 5:10-27.
8. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopaminedepleting agent, tetrabenazine. Arch Gen Psychiat 1972; 5(1):95-9.
9. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiat 1972; 5(1):100-3.
10. Kazamatsuri H, Cole JO. Treatment of tardive dyskinesia. 3. Clinical efficacy of a dopamine competing agent, methyldopa. Arch Gen Psychiat 1972; 5(6):824-7.
11. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiat 2007; 20(2):131-7.
12. Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2010 (in press).
13. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiat 1982; 5(4):473-81.
14. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 5(4):701-5.
15. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8(4 Suppl):52S-6S.
16. Chakos MH, Alvir JM, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiat 1996; 5(4):313-19.
17. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiat 1993; 5(4):133-9.
18. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiat 2004; 5(3):414-25.
19. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiat 2008; 5(2):151-6.
20. Hyde TM AJ, Fisher WC, Egan MF. Tardive dyskinesia. In: Factor S. A. LT, Weiner WJ, ed. Drug Induced Movement Disorders. Second edn. Malden, Oxford, Carlton: Blackwell Publishing, 2005, pp 213-256.
21. Jeste DV, Potkin SG, Sinha S, Feder S, Wyatt RJ. Tardive dyskinesia-reversible and persistent. Arch Gen Psychiat 1979; 5(5):585-90.
22. van Harten PN, Hoek HW, Matroos GE, et al. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiat 1998; 5(4):565-7.
23. Yassa R, Nastase C, Dupont D, Thibeau M. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiat 1992; 5(9):1206-11.
24. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiat 1995; 5(9):756-65.
25. Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S. Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables. Arch Gen Psychiat 1982; 5(4):466-9.
26. Kane J. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE K, DJ, ed. Psychopharmacology; The Fourth Generation of Progress. New York: Raven, 1995, pp 1485-95.
27. Doongaji DR, Jeste DV, Jape NM, et al. Tardive dyskinesia in India: a prevalence study. J Clin Psychopharmacol 1982; 5(5):341-4.
28. Inada T, Ohnishi K, Kamisada M, et al. A prospective study of tardive dyskinesia in Japan. Eur Arch Psychiat Clin Neurosci 1991; 240(4-5):250-4.
29. Miller CH, Simioni I, Oberbauer H, et al. Tardive dyskinesia prevalence rates during a ten-year followup. J Nerv Ment Dis 1995; 5(6):404-7.
30. Hayashi T, Nishikawa T, Koga I, et al. Prevalence of and risk factors for respiratory dyskinesia. Clin Neuropharmacol 1996; 5(5):390-8.
31. Go CL, Rosales RL, Caraos RJ, Fernandez HH. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients. Parkinsonism Relat Disord 2009; 5(9):655-9.
32. Swartz JR, Burgoyne K, Smith M, et al. Tardive dyskinesia and ethnicity: review of the literature. Ann Clin Psychiat 1997; 5(1):53-9.
33. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009; 5(16):2309-15.
34. Wonodi I, Adami HM, Cassady SL, et al. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol 2004; 5(6):592-8.
35. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiat 1991; 5(3):259-63.
36. Woerner MG, Saltz BL, Kane JM, et al. Diabetes and development of tardive dyskinesia. Am J Psychiat 1993; 5(6):966-8.
37. Raja M, Azzoni A. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study. Hum Psychopharmacol 2002; 5(1):61-3.
38. Kane JM, Woerner M, Weinhold P, et al. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984; 5(3):387-9.
39. Chong SA, Sachdev PS, eds. The epidemiology of tardive dyskinesia. NY, NY Marcel Dekker 2004.
40. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiat 1981; 5(12):1618-19.
41. Muller DJ, Schulze TG, Knapp M, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 5(5):375-9.
42. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiat 1997; 5(2):139-45.
43. Segman RH, Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiat 2002; 5(2):137-9.
44. Liao DL, Yeh YC, Chen HM, et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiol 2001; 5(2):95-8.
45. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacol 2002; 5(1):105-19.
46. Ozdemir V, Basile VS, Masellis M, Kennedy JL. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. J Biochem Biophys Methods 2001; 47(1-2):151-7.
47. Bakker PR, van Harten PN, van Os J. Antipsychoticinduced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006; 83(2-3):185-2.
48. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiat 1997; 5(7):827-9.
49. Zai CC, De Luca V, Hwang RW, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiat 2007; 5(9):794-5.
50. Ohmori O, Suzuki T, Kojima H, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998; 5(2):107-13.
51. Lam LC, Garcia-Barcelo MM, Ungvari GS, et al. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiat 2001; 5(6):238-41.
52. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiat 2000; 5(4):410-17.
53. Hori H, Ohmori O, Shinkai T, et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacol 2000; 5(2):170-7.
54. Bakker PR, van Harten PN, van Os J. Antipsychoticinduced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiat 2008; 5(5):544-56.
55. Frank Skidmore WJW, Robert Burke, ed. Neuroleptic induced tardive dyskinesia variants Blackwell, 2008.
56. Fahn S, ed. The Tardive dyskinesias. Edinburgh: Churchill Livingstone, 1984.
57. DeLeon ML JJ. Clinical features and management of tardive dyskinesias, tardive myoclonus, tardive tremor, and tardive tourettism. In: Sethi K, ed. Drug Induced Movement Disorders, New York, NY: Marcel Dekker, Inc, 2004.
58. Frank Skidmore WW, Robert Bruke. Neuroleptic induced tardive dyskinesia variants. In: Factor SA, Lang AE, Weiner WJ, eds. Drug induced movement disorders. Massachusetts: Blackwell, 2005, pp 257-84.
59. FitzGerald P, Jankovic J. Tardive oculogyric crises. Neurol 1989; 5:1434-7.
60. Fahn S JJ, ed. Principles and Practice of Movement Disorders. Philadelphia Churchill Livingstone Elsevier, 2007.
61. Stacy M CF, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurol 1993; 5:937-40.
62. Lang AE. Clinical differences between metoclopramide-and antipsychotic-induced tardive dyskinesias. Can J Neurol Sci 1990; 5(2):137-9.
63. Weiner WJ, Goetz CG, Nausieda PA, Klawans HL. Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med 1978; 5(3):327-31.
64. Samie MR, Dannenhoffer MA, Rozek S. Lifethreatening tardive dyskinesia caused by metoclopramide. Mov Disord 1987; 5(2):125-9.
65. Horiguchi J, Shingu T, Hayashi T, et al. Antipsychoticinduced life-threatening 'esophageal dyskinesia'. Int Clin Psychopharmacol 1999; 5(2):123-7.
66. Molho ES, Feustel PJ, Factor SA. Clinical Comparison of Tardive and Idiopathic Cervical Dystonia. Mov Disord 1998; 5(3):486-9.
67. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurol 1982; 5(12):1335-46.
68. Marsden C.D MRHS, Baldessarini R.J., eds. Extrapyrimidal movement disorders produced by antipsychotic drugs. Oxford University Press.
69. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch Gen Psychiat 1982; 5(7):803-16.
70. Smith JM BR. Changes in prevalence, severity, and recovery in tardive dyskinesia with age Arch Gen Psychiat 1980; 37:1368-73.
71. Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010; 5:893-901.
72. Mejia NI JJ. Metoclopramide-induced tardive dyskinesia in an infant. Mov Dis 2005; 5(1):86-9.
73. Klawans HL, Tanner CM, Barr A. The reversibility of "permanent" tardive dyskinesia. Clin Neuropharmacol 1984; 5(2):153-9.
74. Wegner JT KJ. Follow-up study on the reversibility of tardive dyskinesia. Am J Psychiat 1982; 5(3):368-9.
75. Bergen JA, Eyland EA, Campbell JA, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiat 1989; 5:523-8.
76. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiat 1990; 5:585-92.
77. Tarsy D. Tardive Dyskinesia. Curr Treat Options Neurol 2000; 5(3):205-14.
78. Rittmannsberger H. Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics. Psychiatr Danub 2008; 5(4):461-5.
79. Casey DE. Tardive dyskinesia: reversible and irreversible. Psychopharmacol Suppl 1985; 5:88-97.
80. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiat 1994; 5(6):836-41.
81. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients:14-year follow-up. Neurology 2001; 5(6):805-7.
82. Burke RE. Tardive dyskinesia: current clinical issues. Neurology 1984; 5(10):1348-53.
83. Ghaemi SN, Ko JY. Quetiapine-related tardive dyskinesia. Am J Psychiat 2001; 158(10):1737.
84. Rizos E, Douzenis A, Gournellis R, et al. Tardive dyskinesia in a patient treated with quetiapine. World J Biol Psychiat 2009; 5(1):54-7.
85. Bruscas MJ, Gonzalez F, Santos JL, Sanchez E. Tardive dyskinesia associated with clozapine treatment. Prog Neuropsychopharmacol Biol Psychiat 2007; 5(4):963-4.
86. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiat 1994; 5(11):886-7.
87. Duggal HS, Mendhekar DN. Clozapine-induced tardive dystonia (blepharospasm). J Neuropsychiat Clin Neurosci 2007; 5(1):86-7.
88. Ertugrul A, Demir B. Clozapine-induced tardive dyskinesia: a case report. Prog Neuropsychopharmacol Biol Psychiat 2005; 5(4):633-5.
89. Iqbal MM, Rahman A, Husain Z, et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiat 2003; 5(1):33-48.
90. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiat 1993; 54(9):327-30.
91. Kumet R, Freeman MP. Clozapine and tardive dyskinesia. J Clin Psychiat 2002; 5(2):167-8.
92. Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiat 2009; 10(4 Pt 3):919-24.
93. Mendhekar DN, Duggal HS. Clozapine-induced tardive dyskinesia and hypothyroidism. J Neuropsychiat Clin Neurosci 2006; 5(2):245-6.
94. Miller DD. Clozapine and tardive dyskinesia. Am J Psychiat 2003; 160(3):588.
95. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009; 5:844-56.
96. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008; 5(3):379-84.
97. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 5(1):11-19.
98. Skidmore F, Reich SG. Tardive Dystonia. Curr Treat Options Neurol 2005; 5(3):231-6.
99. Alberts VA, Catalano G, Poole MA. Tardive dyskinesia as a result of long-term prochlorperazine use. South Med J 1996; 5(10):989-91.
100. Factor SA, Matthews MK. Persistent extrapyramidal syndrome with dystonia and rigidity caused by combined metoclopramide and prochlorperazine therapy. South Med J 1991; 5(5):626-8.
101. Hayashi Y, Ohyagi Y, Inoue I, et al. [A case of amoxapine-induced tardive dystonia successfully treated with a low dose anti-cholinergic agent]. Rinsho Shinkeigaku 2000; 5(4):367-71.
102. Huang CC. Persistent tardive dyskinesia associated with amoxapine therapy. Am J Psychiat 1986; 5(8):1069-70.
103. Huang CC. Persistent tardive dyskinesia associated with amoxapine therapy-two case reports. Hillside J Clin Psychiat 1986; 5(2):209-13.
104. Singh GP. Amoxapine-induced tardive dyskinesia. Indian J Psychiat 2009; 51(4):327.
105. Tao GK, Harada DT, Kootsikas ME, et al. Amoxapineinduced tardive dyskinesia. Drug Intell Clin Pharmacol 1985; 19(7-8):548-9.
106. Thornton JE, Stahl SM. Case report of tardive dyskinesia and parkinsonism associated with amoxapine therapy. Am J Psychiat 1984; 5(5):704-5.
107. Chouza C, Scaramelli A, Caamano JL, et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986; 5(8493):1303-4.
108. xFenn DS, Moussaoui D, Hoffman WF, et al. Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacol (Berl) 1996; 5(2):206-10.
109. Casey DE. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiat 1985; 46 (4 Pt 2):42-7.
110. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiat 2000; 61(Suppl 4):5-9.
111. Jankovic J, Tolosa E. Parkinson's Disease and Movement Disorders. Fifth edn: Lippincott Williams & Wilkins, 2006.
112. Seeman P. Dopamine D2 Receptors as treatment targets in schizophrenia. Clin Schizoph Related Psychos, 2010; 56-73.
113. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 5(1):47-62.
114. Watts RL KW. Movement Disorders: Neurologic Principles and Practice, Second edn. McGraw-Hill Professional, 2004.
115. Fahn S JJ. Principles and Practice of Movement Disorders. First edn. Philadelphia: Churchill Livingstone, 2007.
116. Ashby CR, Jr, Hitzemann R, Rubinstein JE, Wang RY. One year treatment with haloperidol or clozapine fails to alter neostriatal D1-and D2-dopamine receptor sensitivity in the rat. Brain Res 1989; 5(1):194-7.
117. Blin J, Baron JC, Cambon H, et al. Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J Neurol Neurosurg Psychiat 1989; 5(11):1248-52.
118. Farde L, Wiesel FA, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiat 1990; 5(3):213-19.
119. Gerlach J. Current views on tardive dyskinesia. Pharmacopsychiat 1991; 5(2):47-8.
120. Stahl SM. "Hit-and-Run" actions at dopamine receptors, part 2: Illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics. J Clin Psychiat 2001; 5(10):747-8.
121. Stahl SM. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics. J Clin Psychiat 2001; 5(9):670-1.
122. Casey DE. Pathophysiology of antipsychotic druginduced movement disorders. J Clin Psychiat 2004; 65(Suppl 9):25-8.
123. Thaker GK, Tamminga CA, Alphs LD, et al. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch Gen Psychiat 1987; 5(6):522-9.
124. Gunne LM, Haggstrom JE. Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacol (Berl) 1983; 5(3):191-4.
125. Perry TL, Hansen S, Jones K. Schizophrenia, tardive dyskinesia, and brain GABA. Biol Psychiat 1989; 5(2):200-6.
126. Seiler N, Grauffel C, Elands J, et al. Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin. Pharmacol Biochem Behav 1995; 5(2):181-9.
127. Auchus AP, Pickel VM. Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induced movement disorders. Exp Neurol 1992; 5(1):17-27.
128. Hong JS, Yang HY, Fratta W, Costa E. Rat striatal methionine-enkephalin content after chronic treatment with cataleptogenic and noncataleptogenic antischizophrenic drugs. J Pharmacol Exp Ther 1978; 5(1):141-7.
129. Tang F, Costa E, Schwartz JP. Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks. Proc Natl Acad Sci USA 1983; 5(12):3841-4.
130. McCormick SE, Stoessl AJ. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. Neurosci 2002; 5(4):851-9.
131. Bishnoi M, Chopra K, Kulkarni SK. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia. Methods Find Exp Clin Pharmacol 2007; 5(3):211-16.
132. Waldmeier PC, Delini-Stula AA. Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 1979; 5(4):363-73.
133. Balsara JJ, Jadhav JH, Muley MP, Chandorkar AG. Effect of drugs influencing central serotonergic mechanisms on methamphetamine-induced stereotyped behavior in the rat. Psychopharmacol (Berl) 1979; 5(3):303-7.
134. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacol (Berl) 1996; 124(1-2):2-34.
135. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiat 1998; 5(9):1207-13.
136. Andreassen OA, Meshul CK, Moore C, Jorgensen HA. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. Psychopharmacol (Berl) 2001; 5(1):11-19.
137. Andreassen OA, Aamo TO, Joorgensen HA. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br J Pharmacol 1996; 5(4):751-7.
138. Maurer I, Moller HJ. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem 1997; 174(1-2):255-9.
139. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998; 5(3):1002-12.
140. Yamada K, Kanba S, Anamizu S, et al. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol Med 1997; 5(5):1223-5.
141. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999; 5(4):731-40.
142. Christensen E, Moller JE, Faurbye A. Neuro pathological investigation of 28 brains from patients with dyskinesia. Acta Psychiatr Scand 1970; 5(1):14-23.
143. Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 5(9):1285-1306.
144. Hori H, Ohmori O, Shinkai T, et al. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 5(8):774-8.
145. Segman RH, Heresco-Levy U, Yakir A, et al. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiat 2002; 5(3):261-3.
146. Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gammaaminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genom 2008; 5(4):317-23.
147. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007; 5(2):159-69.
148. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiat 1991; 5:503-10.
149. Labbate LA, Lande RG, Jones F, Oleshansky MA. Tardive dyskinesia in older out-patients: a follow-up study. Acta Psychiatr Scand 1997; 5(3):195-8.
150. Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003; 5(1):16-27.
151. Huang CC, Wang RI, Hasegawa A, Alverno L. Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol (Berl) 1981; 5(4):359-62.
152. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiat 1999; 5(8):1279-81.
153. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 5(2):358-62.
154. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurol 2006; 66(3):366-72.
155. Esper C.D. FA, Factor S.A. Lingual protrusion dystonia: Frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord 2010; in press.
156. Krause E, Gurkov R. [Local botulinum neurotoxin A therapy in tardive lingual dyskinesia]. Laryngorhinootol 2009; 5(8):508-10.
157. Tschopp L, Salazar Z, Micheli F. Botulinum toxin in painful tardive dyskinesia. Clin Neuropharmacol 2009; 5(3):165-6.
158. Hennings JM, Krause E, Botzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiat 2008; 5(5):1167-71.
159. van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord 2006; 5(8):1276-7.
160. Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiat 2008; 5(2):507-9.
161. Eltahawy HA, Feinstein A, Khan F, et al. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord 2004; 5(8):969-72.
162. Kefalopoulou Z, Paschali A, Markaki E, et al. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand 2009; 5(4):269-73.
163. Schrader C, Peschel T, Petermeyer M, et al. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord 2004; 5(5):583-5.
164. Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiat 2007; 5(2):170-6.
165. Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiat 1984; 5:304-10.
166. Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiat 1984; 5(11):1030-5.
167. Moos DD, Hansen DJ. Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs 2008; 5(5):292-9.
168. Breitbart W. Tardive dyskinesia associated with high-dose intravenous metoclopramide. N Engl J Med 1986; 5(8):518-19.
169. Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed) 1985; 5(6500):930-2.
170. Wiholm BE, Mortimer O, Boethius G, Haggstrom JE. Tardive dyskinesia associated with metoclopramide. Br Med J (Clin Res Ed) 1984; 5(6416):545-7.
171. Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV. Metoclopramide and tardive dyskinesia. Biol Psychiat 1994; 5(9):630-2.
172. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993; 5(12):1469-75.
173. Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after US market withdrawal of cisapride. J Am Pharm Assoc (2003) 2004; 5(6):661-5.
174. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006; 5(3):138-48.
175. Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch Fam Med 1992; 5(2):271-8.
176. Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J 1982; 5(1):23-5.
177. Shearer RM, Bownes IT, Curran P. Tardive akathisia and agitated depression during metoclopramide therapy. Acta Psychiatr Scand 1984; 5(5):428-31.
178. Tarsy D, Indorf G. Tardive tremor due to metoclopramide. Mov Disord 2002; 5(3):620-1.
179. Lavy S, Melamed E, Penchas S. Tardive dyskinesia associated with metoclopramide. Br Med J 1978; 5(6105):77-8.
180. Kaplan S, Staffa JA, Dal Pan GJ. Duration of therapy with metoclopramide: a prescription claims data study. Pharmacoepidemiol Drug Saf 2007; 5(8):878-81.
181. Lattuada E, Cavallaro R, Serretti A, et al. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004; 5(4):489-93.
182. Srivastava V, Varma PG, Prasad S, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genom 2006; 5(2):111-17.
183. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiat 2001; 5(2):225-9.
184. Tan EC, Chong SA, Mahendran R, et al. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiat 2001; 5(2):144-7.
185. de Leon J, Susce MT, Pan RM, et al. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 5(5):448-56.
186. Pae CU, Yu HS, Kim JJ, et al. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol 2004; 5(4):495-500.
187. Liou YJ, Lai IC, Lin MW, et al. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet Genom 2006; 5(3):151-7.
188. Liou YJ, Chen ML, Wang YC, et al. Analysis of genetic variations in the RGS9 gene and antipsychoticinduced tardive dyskinesia in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2009; 150B(2):239-42.
189. Matsumoto C, Shinkai T, Hori H, et al. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiat Res 2004; 127(1-2):1-7.
190. Bharucha KJ, Sethi KD. Tardive tourettism after exposure to neuroleptic therapy. Mov Disord 1995; 5(6):791-3.
191. Stacy M JJ. Tardive tremor. Mov Disord 1992; 5:53-7.
192. Little JT, Jankovic J. Tardive myoclonus. Mov Disord 1987; 5(4):307-11.
193. Tominaga H, Fukuzako H, Izumi K, et al. Tardive myoclonus. Lancet 1987; 1(8528):322.
194. Jankovic J. Drug-Induced and Other Orofacial-Cervical Dyskinesias. Annals of Internal Medicine 1981; 94(6):788.
195. Jankovic J HC, Mejia N, Vuong K. Tetrabenazine: effective treatment for tardive dyskinesia. Mov Disord 2004; 19(Suppl 9):S73.
196. Double DB, Warren GC, Evans M, Rowlands RP. Efficacy of maintenance use of anticholinergic agents. Acta Psychiatr Scand 1993; 5(5):381-4.
197. Soares KV, McGrath JJ. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000(2):CD000204.
198. Tammenmaa IA, Sailas E, McGrath JJ, et al. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a metaanalysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiat 2004; 5(7):1099-1107.
199. Caroff SN, Campbell EC, Havey J, et al. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiat 2001; 5(10):772-5.
200. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiat 1990; 5(4):445-51.
201. Soares K, Rathbone J, Deeks J. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2004(4):CD000203.
202. Emsley R, Turner HJ, Schronen J, et al. A singleblind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiat 2004; 5(5):696-701.
203. Lieberman JA, Alvir J, Mukherjee S, Kane JM. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch Gen Psychiat 1989; 5(10):908-13.
204. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiat 1999; 5(9):836-41.
205. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiat 2003; 5(6):1117-24.
206. Bacher NA, Lewis HA. Propranolol, anxiety, and tardive dyskinesia. J Clin Psychiat 1983; 44(5):196.
207. Bacher NM, Lewis HA. Low-dose propranolol in tardive dyskinesia. Am J Psychiat 1980; 5(4):495-7.
208. Chaudhry R, Radonjic D, Waters B. Efficacy of propranolol in a patient with tardive dyskinesia and extrapyramidal syndrome. Am J Psychiat 1982; 5(5):674-6.
209. Einarson TR. Use of propranolol in treating tardive dyskinesia. Can Med Assoc J 1981; 5(10):1260-2.
210. Kulik FA, Wilbur R. Propranolol for tardive dyskinesia and extrapyramidal side effects (pseudoparkinsonism) from neuroleptics. Psychopharmacol Bull 1980; 5(3):18-19.
211. Moreira MJ, Karniol IG. [Improvement of tardive dyskinesia with high doses of propranolol]. Rev Paul Med 1979; 93(3-4):76-8.
212. Novac A. Improvement in tardive dyskinesia and MMPI scores with propranolol. J Clin Psychiat 1986; 5(4):218-19.
213. Olivera AA, Kiefer MW. Propranolol therapy in a patient with panic disorder, tardive dyskinesia, and essential tremor. J Clin Psychiat 1984; 5(11):484-5.
214. Perenyi A, Farkas A. Propranolol in the treatment of tardive dyskinesia. Biol Psychiat 1983; 5(3):391-4.
215. Pitts FN, Jr. Treatment of tardive dyskinesia with propranolol. J Clin Psychiat 1982; 43(8):304.
216. Risch SC, Cohen RM, Kalin NH. Propranolol, chlorpromazine, and tardive dyskinesia. Am J Psychiat 1980; 137(9):1125.
217. Roberts PW. The use of propranolol in treating tardive dyskinesia. Can Med Assoc J 1980; 5(11):1106-7.
218. Schrodt GR, Jr, Wright JH, Simpson R, et al. Treatment of tardive dyskinesia with propranolol. J Clin Psychiat 1982; 5(8):328-31.
219. Wilbur R, Kulik FA. Propranolol (Inderal) for tardive dyskinesia and extrapyramidal side effects from neuroleptics: possible involvement of beta-adrenergic mechanisms. Prog Neuropsychopharmacol 1980; 5(6):627-32.
220. Hebenstreit GF, Hoffmann H, Hoffmann W, Pittner H. [Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics]. Wien Klin Wochenschr 1986; 5(12):388-92.
221. Browne J, Silver H, Martin R, et al. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia. J Clin Psychopharmacol 1986; 5(2):88-92.
222. Tripodianakis J, Markianos M. Clonidine trial in tardive dyskinesia. Therapeutic response, MHPG, and plasma DBH. Pharmacopsychiat 1986; 19(5):365-7.
223. Woods SW, Saksa JR, Baker CB, et al. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiat 2008; 5(4):546-54.
224. Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997; 5(2):88-91.